CASI Pharmaceuticals, Inc. (CASI): Price and Financial Metrics


CASI Pharmaceuticals, Inc. (CASI): $0.90

-0.05 (-5.22%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add CASI to Watchlist
Sign Up

Industry: Biotech


Ranked

of 476

in industry

CASI POWR Grades


  • CASI scores best on the Growth dimension, with a Growth rank ahead of 80.21% of US stocks.
  • The strongest trend for CASI is in Momentum, which has been heading down over the past 52 weeks.
  • CASI's current lowest rank is in the Momentum metric (where it is better than 4.19% of US stocks).

CASI Stock Summary

  • The ratio of debt to operating expenses for CASI Pharmaceuticals Inc is higher than it is for about just 6.79% of US stocks.
  • Revenue growth over the past 12 months for CASI Pharmaceuticals Inc comes in at 121.49%, a number that bests 94.12% of the US stocks we're tracking.
  • The volatility of CASI Pharmaceuticals Inc's share price is greater than that of 89.46% US stocks with at least 200 days of trading history.
  • Stocks that are quantitatively similar to CASI, based on their financial statements, market capitalization, and price volatility, are CTSO, CLIR, TUFN, AMST, and APDN.
  • Visit CASI's SEC page to see the company's official filings. To visit the company's web site, go to www.casipharmaceuticals.com.

CASI Valuation Summary

  • CASI's price/sales ratio is 10.2; this is 10.13% lower than that of the median Healthcare stock.
  • CASI's price/sales ratio has moved down 40 over the prior 243 months.
  • CASI's price/earnings ratio has moved down 0.6 over the prior 243 months.

Below are key valuation metrics over time for CASI.

Stock Date P/S P/B P/E EV/EBIT
CASI 2021-08-31 10.2 2.4 -4.3 -3.2
CASI 2021-08-30 9.6 2.2 -4.1 -2.9
CASI 2021-08-27 9.8 2.3 -4.1 -3.0
CASI 2021-08-26 9.9 2.3 -4.2 -3.0
CASI 2021-08-25 10.1 2.3 -4.2 -3.1
CASI 2021-08-24 10.4 2.4 -4.4 -3.3

CASI Growth Metrics

  • The 2 year net income to common stockholders growth rate now stands at -265.69%.
  • Its year over year net income to common stockholders growth rate is now at -16.05%.
  • The 3 year net cashflow from operations growth rate now stands at -394.4%.
CASI's revenue has moved up $21,962,000 over the prior 30 months.

The table below shows CASI's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2021-06-30 21.962 -30.203 -51.981
2021-03-31 17.471 -29.253 -53.729
2020-12-31 15.141 -25.886 -48.287
2020-09-30 11.663 -22.672 -46.987
2020-06-30 10.208 -20.59041 -39.68
2020-03-31 7.537 -22.65823 -46.29917

CASI's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • CASI has a Quality Grade of F, ranking ahead of 3.6% of graded US stocks.
  • CASI's asset turnover comes in at 0.158 -- ranking 218th of 682 Pharmaceutical Products stocks.
  • DRNA, RARE, and ALNY are the stocks whose asset turnover ratios are most correlated with CASI.

The table below shows CASI's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.158 0.585 -0.969
2021-03-31 0.139 0.505 -1.192
2020-12-31 0.134 0.372 -1.351
2020-09-30 0.109 0.242 -1.615
2020-06-30 0.101 0.053 -1.638
2020-03-31 0.070 0.052 -2.024

CASI Price Target

For more insight on analysts targets of CASI, see our CASI price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $4.45 Average Broker Recommendation 1.25 (Strong Buy)

CASI Stock Price Chart Interactive Chart >

Price chart for CASI

CASI Price/Volume Stats

Current price $0.90 52-week high $3.90
Prev. close $0.94 52-week low $0.87
Day low $0.88 Volume 592,100
Day high $0.92 Avg. volume 1,638,544
50-day MA $1.12 Dividend yield N/A
200-day MA $1.58 Market Cap 125.12M

CASI Pharmaceuticals, Inc. (CASI) Company Bio


CASI Pharmaceuticals, Inc., a late-stage biopharmaceutical company, acquires, develops, and commercializes therapeutics addressing cancer and other unmet medical needs in China. The company was founded in 1991 and is based in Rockville, Maryland.


CASI Latest News Stream


Event/Time News Detail
Loading, please wait...

CASI Latest Social Stream


Loading social stream, please wait...

View Full CASI Social Stream

Latest CASI News From Around the Web

Below are the latest news stories about CASI Pharmaceuticals Inc that investors may wish to consider to help them evaluate CASI as an investment opportunity.

Wei-Wu He Is The Chairman & CEO of CASI Pharmaceuticals, Inc. (NASDAQ:CASI) And They Just Picked Up 7.8% More Shares

Potential CASI Pharmaceuticals, Inc. ( NASDAQ:CASI ) shareholders may wish to note that the Chairman & CEO, Wei-Wu He...

Yahoo | November 25, 2021

CASI Pharmaceuticals Inc. (NASDAQ: CASI) Stock Forecast: Potential To Pass $6.00 Within A Year

The trading price of CASI Pharmaceuticals Inc. (NASDAQ:CASI) floating lower at last check on Tuesday, November 23, closing at $0.90, -3.88% lower than its previous close. >> 7 Top Picks for the Post-Pandemic Economy

Stocks Register | November 23, 2021

CASI Pharmaceuticals Inc. (NASDAQ: CASI) Stock Forecast 2021: $6.00 Per Share With Bullish Signs

In todays recent session, 2.18 million shares of the CASI Pharmaceuticals Inc. (NASDAQ:CASI) have been traded, and its beta is 0.32. Most recently the companys share price was $0.98, and it changed around $0.05 or 5.25% from the last close, which brings the market valuation of the company to $132.24M. CASI at last check was CASI Pharmaceuticals Inc. (NASDAQ: CASI) Stock Forecast 2021: $6.00 Per Share With Bullish Signs Read More »

Marketing Sentinel | November 22, 2021

5 Penny Stocks Insiders Are Buying

When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision. Below is a look at a few recent notable insider transactions for penny stocks. For more, check out Benzinga's insider transactions platform. Harbor Custom Development The Trade: Harbor Custom Development, Inc. (NASDAQ: HCDI) Director Dennis Andrew Wong acquired a

Yahoo | November 22, 2021

Wei-Wu He Purchases 200,000 Shares of CASI Pharmaceuticals, Inc. (NASDAQ:CASI) Stock

CASI Pharmaceuticals, Inc. (NASDAQ:CASI) CEO Wei-Wu He purchased 200,000 shares of the companys stock in a transaction that occurred on Wednesday, November 17th. The shares were purchased at an average price of $0.99 per share, for a total transaction of $198,000.00. The purchase was disclosed in a filing with the SEC, which is available at []

Transcript Daily | November 21, 2021

Read More 'CASI' Stories Here

CASI Price Returns

1-mo -16.67%
3-mo -40.40%
6-mo -43.75%
1-year -62.81%
3-year -76.98%
5-year -37.50%
YTD -69.49%
2020 -4.53%
2019 -23.13%
2018 23.69%
2017 182.61%
2016 19.79%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 1.4111 seconds.